Hype ETFs approach $900 million and highlight institutional demand.
- Hype ETFs accumulate nearly US$900 million.
- Net inflows reach US$153 million.
- Hype staking increases the attractiveness of ETFs.
The first spot ETFs for HYPE have been trading for about a month and are already showing numbers that are attracting market attention. Products focused on Hyperliquid's cryptocurrency have accumulated a volume close to US$900 million, indicating consistent demand from investors seeking regulated exposure to the asset.
Currently, three asset managers offer ETFs linked to HYPE. The THYP product from 21Shares, BHYP from Bitwise, and HYPG from Grayscale allow investors to access the token through traditional investment platforms. Together, these funds have registered approximately US$153 million in net inflows since their launch.
The initial performance of ETFs has been closely monitored because HYPE possesses characteristics that differentiate it from many other digital assets. One of the main factors highlighted by the market is the direct relationship between the activity of the Hyperliquid platform and the demand for the token.
This is because approximately 97% of the trading fees generated by Hyperliquid are allocated to the so-called Assistance Fund. This mechanism uses the resources to automatically repurchase HYPE tokens, creating a connection between the growth in trading volume on the platform and the demand for the asset.
Another relevant aspect is that the three ETFs hold HYPE in direct custody and pass on to investors the rewards obtained through staking. Under the current network conditions, the annual return is around 2,25%.
Rewards are accumulated continuously, distributed daily, and automatically reinvested in products. Currently, approximately 45% of the entire eligible supply is locked in stakes, equivalent to about 434 million HYPE tokens.
Although all three ETFs have attracted investor interest, trading volume has not been uniform. Bitwise and 21Shares products have accounted for the majority of activity observed so far, while the more recently launched Grayscale fund is still expanding its market share.
The coming months will be closely watched by industry participants. The maintenance of capital inflows could serve as a more consistent indicator of institutional conviction regarding the hype, beyond the enthusiasm typically associated with the initial launch period of new ETFs. Meanwhile, the market is also monitoring Bitcoin spot ETFs in the United States, which are approaching the $2 trillion mark in cumulative trading volume despite recent outflows.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"
Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
Crypto prices
More
